Supplementary Table 1. Proportion of participants with inflammatory bowel disease or immunocompromise by presence of severe baseline disease or recurrence

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Inflammatory bowel disease n (%) |  | Immunocompromisedan (%) |  |
|  | Yes | No |  | Yes | No |  |
| Severe baseline disease |  |  | *P* value |  |  | *P* value |
| Yes | 1(7.1%) | 33(23.2%) | 0.31 | 9(11.0%) | 25(33.8%) | <0.001 |
| No | 13(92.9%) | 109(76.8%) | 73(89.0%) | 49(66.2%) |
| Recurrence |  |  |  |  |  |  |
| Yes | 2(8.7%) | 15(9.2%) | 1.00 | 9(10.2%) | 8(8.1%) | 0.62 |
| No | 21(91.3%) | 149(90.9%) | 79(89.8%) | 91(91.9%) |

aImmunocompromised defined as any of the following at the time of diagnosis of *C. difficile* infection: malignancy with receipt of active chemotherapy, hematopoietic stem cell transplant recipient on immunosuppression or with graft vs. host disease, or history of solid organ transplantation